ImmunityBio and NantKwest Complete Merger • Disaster Recovery Journal
EX-99.1
ImmunityBio to begin Covid-19 vaccine candidate trial in South Africa
NantKwest and ImmunityBio work on Covid-19 vaccines and drugs - Pharmaceutical Technology
Medical Studies & Immunotherapies - Advanced Clinical Research
ImmunityBio Acquires Manufacturing Facility In New York | Contract Pharma
Medical Studies & Immunotherapies - Advanced Clinical Research
Immunotherapy by ImmunityBio - Cell Therapy for Cancer
Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio tech -
ImmunityBio and Amyris conclude Covid-19 vaccine commercialisation JV
El Segundo firm to begin Phase 1 clinical trial for COVID vaccine - Los Angeles Times
ImmunityBio receives FDA approval for Phase I trial of Covid-19 vaccine
Medical Studies & Immunotherapies - Advanced Clinical Research
ImmunityBio, Inc. (@ImmunityBio) / Twitter
ImmunityBio Combines Supercomputing Power with Microsoft Azure to Target Infection “Doorway” of the Coronavirus - ImmunityBio
ImmunityBio's Covid-19 vaccine induces robust T cell response in trial
EX-99.1
NantKwest, ImmunityBio Advance Cell Therapies/Vaccines Against COVID
ImmunityBio Strikes Deals in Effort to Speed Development of Covid Vaccine - Los Angeles Business Journal
ImmunityBio, Inc. (@ImmunityBio) / Twitter
ImmunityBio trying to find solid ground | News, Sports, Jobs - Observer Today
Immunotherapy by ImmunityBio - Cell Therapy for Cancer
Immunotherapy by ImmunityBio - Cell Therapy for Cancer
ImmunityBio, Inc. (@ImmunityBio) / Twitter
Investor Relations - ImmunityBio, Inc.
Fighting a war on two fronts: ImmunityBio targets cancer and COVID-19
